CIK 0001084267
- Non-accelerated filer
- Smaller reporting company
Mobiquity Technologies, Inc.
Sign in to watch- Tickers
- MOBQ MOBQW
- Exchange
- OTC
- Industry
- Services-Advertising
- FY end
- Dec 31
- Incorporated
- NY
- Entity type
- Operating
- EIN
- 113427886
- Phone
- +1 516-256-7766
- Business address
- 35 TORRINGTON LANE, SHOREHAM, NY, 11786
- Former names
- ACE MARKETING & PROMOTIONS INC
Securities
- MOBQ Common stock OTC
- MOBQW Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-31 | Salkind Gene Director | Grant or award · Common Stock Options | +250,000 | 761,544 | ||
| 2025-09-15 | Salkind Gene Director | Grant or award | +25,000 | $1.00 | $25K | 8,668,695 |
| 2025-09-15 | Salkind Gene Director | Grant or award · Convertible notes | +100,000 | 511,544 | ||
| 2024-12-30 | Salkind Gene Director | Option exercise | +420,000 | $0.50 | $210K | 8,643,695 |
| 2024-12-30 | Salkind Gene Director | Option exercise · Convertible notes | −210,000 | 411,544 | ||
| 2024-10-08 | Salkind Gene Director | Grant or award · Common Stock Options | +250,000 | 831,544 | ||
| 2024-08-06 | Salkind Gene Director | Conversion | +7,675,160 | $0.20 | $1.5M | 8,223,695 |
| 2024-08-06 | Salkind Gene Director | Conversion · Series H Preferred Stock | −751,973 | 581,544 | ||
| 2024-08-06 | Salkind Gene Director | Conversion | +7,675,160 | $0.20 | $1.5M | 8,223,695 |
| 2024-08-06 | Salkind Gene Director | Conversion · Series H Preferred Stock | −751,973 | 616,201 | ||
| 2024-07-25 | Salkind Gene Director | Grant or award · Convertible Promissory Notes | +50,000 | 8,135,931 | ||
| 2024-06-27 | Salkind Gene Director | Grant or award · Convertible Promissory Notes | +160,000 | 8,035,931 | ||
| 2023-12-19 | Salkind Gene Director | Grant or award · Common stock options | +100,000 | 7,715,931 | ||
| 2023-12-15 | Salkind Gene Director | Grant or award · Preferred Stock Series G | −300,789 | 3,103,990 | ||
| 2023-12-15 | Salkind Gene Director | Returned to the company · Preferred Stock Series H | +751,973 | 7,615,931 | ||
| 2023-11-07 | Salkind Gene Director | Exercise or conversion · Common Stock | −0 | 96,100 | ||
| 2023-11-07 | Salkind Gene Director | Grant or award · Preferred Stock | +300,789 | 3,103,990 | ||
| 2023-10-06 | Salkind Gene Director | Grant or award | +150,000 | $0.65 | $98K | 448,535 |
| 2023-10-06 | Salkind Gene Director | Grant or award · Common Stock | +0 | 524,671 | ||
| 2023-10-06 | Salkind Gene Director | Grant or award | +150,000 | $0.65 | $98K | 448,535 |
Page 1 of 3 · 54 trades